Is Pazopanib available in India?

It is understood that pazopanib (Pazopanib) may not be produced in India yet, but pazopanib may be sold in India. Oral anti-angiogenic tyrosine kinase inhibitor (TKI) Pazopanib is a multi-target TKI. Its main activity is against vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3, platelet-derived growth factor receptor (PDGFR) and KIT.

Clinical studies have shown that progression-free survival (PFS) in patients with metastatic soft tissue sarcoma increased from 1.6 months in the placebo group to 4.6 months in the pazopanib group. Pazopanib was also effective against renal cell carcinoma (RCC), with PFS increasing from 4.2 months in the placebo group to 9.2 months in the pazopanib group. Overall survival (OS) was also significantly increased with pazopanib treatment despite crossover from placebo to pazopanib treatment. The recommended starting dose per package insert for pazopanib is 800 mg once daily.

PazopanibThe original drug has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be around 3,000 yuan. The price of pazopanib original drug specifications200mg*30 tablets marketed overseas may be around 1,000 RMB per box (the price may fluctuate due to exchange rates). There are also pazopanib generic drugs produced in other countries. The price of 200mg*30 tablets produced by Bangladesh pharmaceutical factory may be around 500 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.